This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
Thyroid Eye Disease: Conversations on Comprehensive Comanagement: Monitoring (CE/CME Podcast) - Part 3
MedEdicus Podcasts
24 minutes
8 months ago
Thyroid Eye Disease: Conversations on Comprehensive Comanagement: Monitoring (CE/CME Podcast) - Part 3
This podcast, Part 3 of a 3-part series on thyroid eye disease (TED), examines the multidisciplinary management of TED with a focus on teprotumumab-associated adverse effects. Through expert discussions and case-based examples, listeners will learn best practices for managing hyperglycemia, hearing changes, and other potential complications. The session outlines the essential role of primary eye care professionals in comanaging TED, from early recognition to educating patients and coordinatin...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
